Given the limitations of sample sizes and individual variability, these findings warrant careful interpretation [8]
These results translated to significant proportions of participants achieving clinically meaningful weight loss: 5% or More Weight Reduction: 92% (4 mg), 100% (8 mg), 100% (12 mg), and 27% (placebo) 10% or More Weight Reduction: 75% (4 mg), 91% (8 mg), 93% (12 mg), and 9% (placebo) 15% or More Weight Reduction: 60% (4 mg), 75% (8 mg), 83% (12 mg), and 2% (placebo) These data underscore retatrutides potential to deliver unprecedented weight loss in a significant portion of individuals with obesity
UK risk stratification uses the FIB-4 score: low risk is 2.67 at any age
10.1016/j.drudis.2013.02.003 24 BlombergM.ZachariaeC.GrnhjF
Research institutions and pharmaceutical companies regularly conduct studies that may offer free medication to eligible participants